ESMO Immuno-Oncology 2022 | Optimizing neoadjuvant therapy in NSCLC with biomarker research

Si-Yang Liu, MD, Guangdong Lung Cancer Institute, Guangzhou, China, talks on unmet needs in non-small cell lung cancer (NSCLC), including the lack of biomarkers of efficacy in neoadjuvant treatment. Whilst three cycles of treatment are typically administered, novel biomarkers will enable personalized treatment and monitoring of patient progress. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.